Skip to main content
SpringerLink
Log in

Ticagrelor cost effective in high risk subgroups?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis In Myocardial Infarction 54

  2. 2016 US dollars

References

  1. Magnuson EA et al. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction : Results From the PEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology 70: 527-538, No. 5, 1 Aug 2017. Available from: URL: https://doi.org/10.1016/j.jacc.2017.05.063.

  2. Navarese EP, et al. Striking the Balance Between Benefits and Costs of Ticagrelor Beyond 1 Year After Myocardial Infarction. Journal of the American College of Cardiology 70: 539-541, No. 5, 1 Aug 2017. Available from: URL: https://doi.org/10.1016/j.jacc.2017.06.025.

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ticagrelor cost effective in high risk subgroups?. PharmacoEcon Outcomes News 784, 28 (2017). https://doi.org/10.1007/s40274-017-4239-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4239-6

Search

Navigation